Lupus eritematoso cutáneo subagudo inducido por golimumab

Blasco-Morente, Gonzalo; Notario-Ferreira, Irene; Rueda-Villafranca, Beatriz; Tercedor-Sánchez, Jesús.
Med. clín (Ed. impr.) ; 145(5): 226-227, sept. 2015.
Artículo en Español | IBECS (España) | ID: ibc-139675

Documentos relacionados

  1. Comparison of the SLE Risk Probability Index (SLERPI) scale against the European League Against Rheumatism/American College of Rheumatology (ACR/EULAR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria.
  2. Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-α antagonists and rituximab therapy?
  3. Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature: A monocentric study of 149 patients.
  4. Immunosuppressive Treatment for an anti-U<sub>1</sub> Ribonucleoprotein Antibody-positive Patient with Pulmonary Arterial Hypertension.
  5. Cutaneous characteristics and association with antinuclear antibodies in 402 patients with different subtypes of lupus erythematosus.
  6. The role of Syk in cutaneous lupus erythematosus.
  7. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
  8. Genomic Identification of Low-Density Granulocytes and Analysis of Their Role in the Pathogenesis of Systemic Lupus Erythematosus.
  9. Subacute cutaneous lupus erythematosus on the lines of Blaschko.
  10. Anti-SS-A (Ro) antibody is positively associated with steroid-induced psychiatric events in systemic lupus erythematosus patients.